ARNIs, particularly sacubitril/valsartan, were introduced following the landmark Prospective Comparison of ARNI With Angiotensin-Converting Enzyme Inhibitor (ACEI) to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial [5], which demonstrated substantial reductions in cardiovascular mortality and heart failure hospitalizations compared to enalapril. Here, ACE is linked to heart failure.